July 2026

The Pak-China Business Conference concluded with $1.4 Billion in total investment commitments, including 42 final-day deals! 🚀 This historic partnership focuses on: Local Active Pharmaceutical Ingredient (API) Manufacturing Vaccine Production Advanced Medical Equipment These commitments mark a pivotal step toward reducing reliance on imports, boosting exports, and strengthening national healthcare self-reliance.

Tomorrow in Islamabad, the Pakistan–China B2B Investment Conference kicks off, bringing together over 450+ firms to forge the Sino-Pak Pharma Alliance. With the support of DRAP, BOI, and SIFC, this summit isn’t just about discussions—it is about immediate, project-driven results. Dedicated on-site regulatory desks will be active to instantly fast-track licensing and joint venture approvals,

A new era of healthcare transparency begins. The Drug Regulatory Authority of Pakistan (DRAP) has established critical regulatory timelines to safeguard public health: The Pakistan Pharmaceutical Manufacturers Association (PPMA) strongly welcomes these landmark regulatory milestones, standing united with DRAP in this definitive victory for national patient safety and pharmaceutical innovation.

Under the newly announced Federal Budget 2026-27, the government has officially exempted customs duties on critical cancer-related Active Pharmaceutical Ingredients (APIs). This public health relief will significantly reduce manufacturing costs and make life-saving cancer treatments much more affordable across Pakistan.